Glyburide

Introduction Overview

Generic Name

glyburide

Brand Name

DiaBeta, Glynase PresTab, Micronase

Dosage Form

Oral tablet

Drug Class

Sulfonylureas

Pharmacokinetics

Absorption:
Glyburide is administered orally and exhibits good absorption from the gastrointestinal tract. After oral administration, peak plasma concentrations are usually reached within 4 hours, although onset of action may begin as early as 2.5 hours post-dose. The drug is rapidly absorbed but undergoes significant first-pass metabolism in the liver, which modulates its bioavailability. Food does not substantially affect the absorption, so glyburide is often administered with or just before the first main meal of the day to optimize glycemic effect and reduce hypoglycemia risk.

Distribution:
Glyburide is extensively bound to plasma proteins, primarily albumin, with an estimated binding of approximately 99%. This high protein binding limits free drug concentrations in plasma but facilitates a relatively stable pharmacokinetic profile. The volume of distribution is moderate, reflecting distribution mainly in the plasma and extracellular fluids rather than extensive tissue binding. Its lipophilicity allows penetration into pancreatic beta cells where it exerts its hypoglycemic effect.

Metabolism:
The drug undergoes extensive hepatic metabolism primarily via the cytochrome P450 enzyme system, especially CYP2C9 isoenzyme. Metabolism results in the formation of active and inactive metabolites. Two major active metabolites have been identified which contribute modestly to overall hypoglycemic activity but have a longer half-life than the parent compound. Hepatic impairment can significantly alter glyburide metabolism, increasing the risk of hypoglycemia.

Elimination:
Glyburide and its metabolites are eliminated primarily via biliary and renal excretion. Approximately 50% is excreted in the urine and the remainder in the feces, mostly as metabolites. The elimination half-life ranges from 4 to 10 hours but can be prolonged in patients with renal dysfunction. These pharmacokinetic properties necessitate careful dose adjustment and monitoring in patients with liver or kidney impairment to avoid adverse glycemic events.

Dosage Forms

Available Dosage Forms:
Glyburide is commercially available in oral tablet formulations including:
- Standard glyburide tablets: 1.25 mg, 2.5 mg, 5 mg
- Micronized glyburide tablets: 0.75 mg, 1.5 mg, 3 mg
- Brand-specific formulations such as DiaBeta, Glynase PresTab, and Micronase also provide standard or micronized glyburide tablets.

Dosages for Adults and Adolescents:
- Standard glyburide initial dose ranges from 2.5 mg to 5 mg orally once daily, generally administered with breakfast or the first main meal.
- Dose titration is performed in increments of no more than 2.5 mg weekly, based on blood glucose monitoring.
- Maintenance doses range from 1.25 mg to 20 mg per day, given as a single dose or divided doses.
- Maximum daily dose is 20 mg.
- Micronized glyburide has an initial dose of 1.5 mg to 3 mg orally once daily with titration increments no more than 1.5 mg weekly.
- Maintenance dose ranges from 0.75 mg to 12 mg per day; maximum dose is 12 mg.
- Lower starting doses are recommended for patients sensitive to hypoglycemia, including elderly patients (initial 1.25 to 2.5 mg standard or 0.75 to 1.5 mg micronized).

Specific Patient Populations:
- Older adults require lower initial doses to minimize hypoglycemia risk.
- Dose adjustments are recommended in renal or hepatic impairment due to altered metabolism and elimination.
- Transition from insulin or other oral hypoglycemics should be managed cautiously: if insulin dose <20 units/day, start 2.5 to 5 mg (standard) or 1.5 to 3 mg (micronized) glyburide; for insulin 20–40 units/day, substitute 5 mg (standard) or 3 mg (micronized); above 40 units/day, insulin should be decreased by 50% concomitantly with starting 5 mg (standard) or 3 mg (micronized) glyburide, titrating as insulin is withdrawn.
- Glyburide is administered once daily preferably with breakfast, but some patients, particularly on higher doses, may benefit from twice daily dosing.
- Close blood glucose monitoring is essential during dose initiation or adjustments.

Mechanism Of Action

Glyburide is a potent oral hypoglycemic agent belonging to the sulfonylurea class, exerting its effects primarily by stimulating insulin secretion from pancreatic beta cells. The drug binds selectively to the sulfonylurea receptor 1 (SUR1), which is a subunit of the ATP-sensitive potassium (K_ATP) channels in the beta cell membrane.

Binding of glyburide to the SUR1 receptor inhibits the K_ATP channels, resulting in closure of these channels. This causes membrane depolarization that opens voltage-dependent calcium channels, leading to an influx of calcium ions into the beta cells. Elevated intracellular calcium triggers exocytosis of insulin-containing secretory granules, increasing insulin release into the circulation.

Apart from enhancing insulin secretion, glyburide may increase the sensitivity of peripheral tissues to insulin, although the primary clinical effect is through insulin release. It also suppresses hepatic gluconeogenesis indirectly by augmented insulin activity. Unlike some older sulfonylureas, glyburide and its micronized formulations have a more predictable pharmacodynamic profile and lower variability in onset and duration of action.

Clinically, this mechanism effectively lowers fasting and postprandial blood glucose levels in type 2 diabetes patients who retain some functional beta cell activity. Glyburide is ineffective in type 1 diabetes mellitus where beta cell function is absent. Research has demonstrated that sulfonylureas like glyburide provide glycemic control but require dose titration to balance efficacy with the risk of hypoglycemia. Compared to other sulfonylureas, glyburide tends to have a slightly higher hypoglycemia risk, mandating careful patient selection and monitoring.

Pharmacological Actions

Stimulates pancreatic beta cell insulin secretion by inhibiting ATP-sensitive potassium channels.
Lowers blood glucose concentration by increasing circulating insulin levels.
Enhances peripheral insulin sensitivity to a modest degree.
Suppresses hepatic glucose output indirectly through increased insulin levels.
Prolonged hypoglycemic effect due to active metabolites with extended half-life.
Reduces both fasting and postprandial plasma glucose concentrations.
Micronized form provides more consistent absorption and pharmacodynamic response.
Facilitates improved glycemic control when used adjunctively with diet and exercise.
Does not treat type 1 diabetes mellitus due to lack of endogenous insulin secretion.
Potential to cause hypoglycemia, especially in susceptible populations or overdose.

Therapeutic Or Clinical Uses

Management of type 2 diabetes mellitus as adjunct to diet and exercise to improve glycemic control.
Used to lower blood glucose levels in adult patients with functional pancreatic beta cells.
Therapeutic option when metformin or lifestyle modifications alone are insufficient for glycemic control.
Alternative oral hypoglycemic agent in patients intolerant to other antidiabetic drugs.
Useful in patients transitioning from insulin therapy to oral hypoglycemic agents based on residual beta cell function.
Employed in combination therapy with other oral antidiabetics when monotherapy is inadequate.
Potential use in geriatric populations with careful dose adjustment and monitoring.
Adjunct treatment to reduce risk of long-term diabetes complications by improving glucose regulation.
Not indicated for type 1 diabetes mellitus or diabetic ketoacidosis.
Occasionally used for off-label indications related to hyperglycemia management under specialist supervision.

Side Or Adverse Effects

Hypoglycemia is the most common and clinically significant adverse effect, particularly with overdose or in sensitive populations.
Nausea and gastrointestinal discomfort including heartburn and feeling full.
Mild skin reactions including rash, redness, and mild itching.
Blurred vision possibly related to rapid changes in blood glucose levels.
Muscle or joint pain reported occasionally during therapy.
Rare but serious allergic reactions including hives, swelling, and anaphylaxis.
Severe cutaneous adverse reactions such as Stevens-Johnson syndrome and toxic epidermal necrolysis have been reported rarely.
Hematologic side effects including hemolytic anemia, thrombocytopenia, leukopenia, and pancytopenia in susceptible individuals.
Jaundice or elevated liver enzymes indicating hepatic involvement.
Symptoms associated with hyponatremia including headache, confusion, slurred speech, vomiting, and coordination loss.
Photosensitivity reactions leading to increased risk of sunburn; patients advised to use sunscreen and protective clothing.
Rare episodes of severe skin rash, redness, or itching warranting discontinuation.
Elderly patients may have increased sensitivity to hypoglycemia and other adverse effects.
Symptoms of hypoglycemia include headache, hunger, weakness, sweating, tremor, irritability, dizziness, and tachycardia.
Severe hypoglycemia can cause confusion, seizures, loss of consciousness, and requires emergency treatment.

Precautions

Screen for sulfa allergy prior to initiating therapy due to potential cross-reactivity.
Exercise caution in patients with glucose-6-phosphate dehydrogenase deficiency (G6PD) due to risk of hemolytic anemia.
Adjust dosing and monitor carefully in patients with liver or kidney impairment.
Avoid use in type 1 diabetes mellitus or patients with diabetic ketoacidosis.
Monitor blood glucose regularly to avoid unrecognized hypoglycemia.
Educate patients to recognize and promptly treat symptoms of hypoglycemia.
Consider dose reduction in elderly patients and those with risk factors for hypoglycemia.
Avoid alcohol consumption which may potentiate hypoglycemia or interfere with glycemic control.
Inform patients about potential photosensitivity; recommend sun protection measures.
Evaluate concomitant medications for drug interactions that may alter glyburide efficacy or toxicity.
Use with caution when switching from insulin or other hypoglycemic agents; follow protocols to avoid hypoglycemia or hyperglycemia.
Pregnancy and breastfeeding require assessment of risks versus benefits; glycemic control is crucial in pregnancy.
Patients with nerve disorders affecting autonomic functions may need close monitoring.
Proper storage of medication away from moisture and heat to preserve drug stability.
Ensure patients understand not to double doses if a dose is missed; follow proper dosing schedules.

Warnings

Contraindicated in patients with type 1 diabetes mellitus or diabetic ketoacidosis.
Do not use concomitantly with bosentan due to potential drug interaction.
Risk of serious hypoglycemia, potentially life-threatening, especially in overdose or renal/hepatic impairment.
Hypoglycemia risk increased with prolonged exercise, skipped meals, alcohol intake, or certain drug interactions.
Not recommended for controlling blood sugar during pregnancy without physician guidance.
Severe allergic and dermatologic reactions may occur; discontinue immediately if symptoms develop.
Monitor for signs of hyponatremia and electrolyte disturbances during therapy.
Use cautiously in patients with cardiovascular disease; glyburide may increase cardiac event risk in some patients.
Elderly patients are more susceptible to hypoglycemic episodes with glyburide use.
Adjust therapy if concomitant medications affecting blood sugar or metabolism are initiated or stopped.
Avoid sudden discontinuation which may lead to rebound hyperglycemia or diabetic complications.
Patients should carry glucose sources at all times to treat acute hypoglycemia episodes.
Emergency glucagon injection kits should be available for severe hypoglycemia management.
Risk-benefit assessment mandatory in patients with co-morbidities impacting drug metabolism or clearance.
Patients should inform healthcare providers of glyburide use prior to any surgical or medical procedures.

Contraindication

Known allergy or hypersensitivity to glyburide or other sulfonylurea compounds.
Type 1 diabetes mellitus due to absence of pancreatic beta cell function.
Diabetic ketoacidosis, with or without coma, as insulin therapy is required.
Concomitant treatment with bosentan due to drug interactions.
Severe liver disease or significant hepatic insufficiency impairing drug metabolism.
Severe renal impairment where drug accumulation increases hypoglycemia risk.
Patients with history of sulfa drug hypersensitivity may be contraindicated depending on clinical judgment.
Pregnancy unless specifically advised by a healthcare provider weighing risks and benefits.
Lactation if breastfeeding infants are at risk; alternative therapies or monitoring recommended.
Patients with active hemolytic anemia, especially related to G6PD deficiency.
Situations requiring rapid insulin action such as severe illness, surgery, or trauma.
Hypoglycemia unawareness or frequent severe hypoglycemic episodes without adequate monitoring.

Drug Interactions

Bosentan: Concurrent use is contraindicated due to reduced glyburide efficacy and safety concerns.
Colesevelam: Requires dosing separation; take glyburide at least 4 hours before colesevelam to avoid absorption interference.
Other antidiabetic agents: Combination therapy may increase hypoglycemia risk requiring close monitoring.
Alcohol: Potentiates hypoglycemic effects and may disrupt glucose control.
Beta-blockers: May mask hypoglycemia symptoms and blunt adrenergic responses.
Nonsteroidal anti-inflammatory drugs (NSAIDs) and salicylates: Can enhance hypoglycemia.
Thiazide diuretics: May antagonize glyburide effect leading to hyperglycemia.
Anticoagulants: Potential interaction affecting blood glucose levels.
CYP2C9 inhibitors or inducers may modify glyburide metabolism altering plasma levels and efficacy.
Corticosteroids and sympathomimetics may reduce hypoglycemic effect of glyburide.
Herbal products and supplements such as ginseng or fenugreek can affect glycemic control.
MAO inhibitors may potentiate hypoglycemic effect.
Certain antibiotics like sulfonamides and chloramphenicol may increase hypoglycemia risk.
Thyroid drugs can either potentiate or diminish glyburide efficacy.
Phenylbutazone and fluconazole may increase hypoglycemia risk by impacting metabolism.

Preparations Of The Drug

DiaBeta: Oral tablets available in 1.25 mg, 2.5 mg, and 5 mg strengths.
Micronase: Micronized glyburide tablets in 0.75 mg, 1.5 mg, and 3 mg strengths with improved absorption characteristics.
Glynase PresTab: Micronized glyburide tablets designed for more consistent bioavailability, available in standardized doses.
Glycron: Standard glyburide oral tablets used for glycemic control.
Various generic formulations of standard and micronized glyburide tablets with differing excipients.
Tablets intended for oral administration, taken preferably once daily with or before breakfast.
Packaging typically includes bottles with child-resistant caps and blisters with specified tablet strengths.
Formulations manufactured under strict quality and stability standards to ensure consistent dosing.
Tablets must be stored at room temperature away from moisture and heat for optimal stability.
Available in both branded and generic forms to accommodate patient affordability and accessibility.